These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28427595)

  • 1. Vasomotor Response to Nitroglycerine Over 5 Years Follow-Up After Everolimus-Eluting Bioresorbable Scaffold Implantation.
    Dudek D; Rzeszutko Ł; Onuma Y; Sotomi Y; Depukat R; Veldhof S; Ediebah D; Staehr P; Zasada W; Malinowski KP; Kaluza GL; Serruys PW
    JACC Cardiovasc Interv; 2017 Apr; 10(8):786-795. PubMed ID: 28427595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasomotor Function Comparative Assessment at 1 and 2 Years Following Implantation of the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold and the Xience V Everolimus-Eluting Metallic Stent in Porcine Coronary Arteries: Insights From In Vivo Angiography, Ex Vivo Assessment, and Gene Analysis at the Stented/Scaffolded Segments and the Proximal and Distal Edges.
    Gogas BD; Benham JJ; Hsu S; Sheehy A; Lefer DJ; Goodchild TT; Polhemus DJ; Bouchi YH; Hung OY; Yoo SY; Joshi U; Giddens DP; Veneziani A; Quyyumi A; Rapoza R; King SB; Samady H
    JACC Cardiovasc Interv; 2016 Apr; 9(7):728-41. PubMed ID: 27056313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term invasive follow-up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities.
    Simsek C; Karanasos A; Magro M; Garcia-Garcia HM; Onuma Y; Regar E; Boersma E; Serruys PW; van Geuns RJ
    EuroIntervention; 2016 Jan; 11(9):996-1003. PubMed ID: 25349042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents: Insights of the TROFI II Trial.
    Gomez-Lara J; Brugaletta S; Ortega-Paz L; Vandeloo B; Moscarella E; Salas M; Romaguera R; Roura G; Ferreiro JL; Teruel L; Gracida M; Windecker S; Serruys PW; Gomez-Hospital JA; Sabaté M; Cequier A
    JACC Cardiovasc Interv; 2018 Aug; 11(16):1559-1571. PubMed ID: 29805111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial 5-Year Evaluation of Side Branches Jailed by Bioresorbable Vascular Scaffolds Using 3-Dimensional Optical Coherence Tomography: Insights From the ABSORB Cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Grundeken MJ; Nakatani S; Asano T; Sotomi Y; Foin N; Ng J; Okamura T; Wykrzykowska JJ; de Winter RJ; van Geuns RJ; Koolen J; Christiansen EH; Whitbourn R; McClean D; Smits P; Windecker S; Ormiston JA; Serruys PW
    Circ Cardiovasc Interv; 2017 Sep; 10(9):. PubMed ID: 28893770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging.
    Tenekecioglu E; Serruys PW; Onuma Y; Costa R; Chamié D; Sotomi Y; Yu TB; Abizaid A; Liew HB; Santoso T
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1115-1130. PubMed ID: 28527768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial.
    Baron SJ; Lei Y; Chinnakondepalli K; Vilain K; Magnuson EA; Kereiakes DJ; Ellis SG; Stone GW; Cohen DJ;
    JACC Cardiovasc Interv; 2017 Apr; 10(8):774-782. PubMed ID: 28427593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular compliance changes of the coronary vessel wall after bioresorbable vascular scaffold implantation in the treated and adjacent segments.
    Brugaletta S; Gogas BD; Garcia-Garcia HM; Farooq V; Girasis C; Heo JH; van Geuns RJ; de Bruyne B; Dudek D; Koolen J; Smits P; Veldhof S; Rapoza R; Onuma Y; Ormiston J; Serruys PW
    Circ J; 2012; 76(7):1616-23. PubMed ID: 22531596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and Functional Evaluation of Coronary Arteries Treated With ABSORB Bioresorbable Vascular Scaffold at 5-Year Follow-Up.
    Goncalves-Ramírez LR; Amat-Santos IJ; Altisent OA; Gutiérrez H; Pérez de Prado A; Adeliño R; Gómez I; Fernández-Vázquez F; San Román A; Puri R
    Am J Cardiol; 2022 Nov; 182():1-7. PubMed ID: 36075756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
    Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preserved endothelial vasomotor function after everolimus-eluting stent implantation.
    Roura G; Homs S; Ferreiro JL; Gomez-Lara J; Romaguera R; Teruel L; Sánchez-Elvira G; Ariza-Solé A; Gómez-Hospital JA; Cequier Á
    EuroIntervention; 2015 Oct; 11(6):643-9. PubMed ID: 25022229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow-up: a patient level insight into the ABSORB A clinical trial.
    Sarno G; Bruining N; Onuma Y; Garg S; Brugaletta S; De Winter S; Regar E; Thuesen L; Dudek D; Veldhof S; Dorange C; Garcia-Garcia HM; Ormiston JA; Serruys PW
    Int J Cardiovasc Imaging; 2012 Jan; 28(1):51-8. PubMed ID: 21213050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy?
    Brugaletta S; Heo JH; Garcia-Garcia HM; Farooq V; van Geuns RJ; de Bruyne B; Dudek D; Smits PC; Koolen J; McClean D; Dorange C; Veldhof S; Rapoza R; Onuma Y; Bruining N; Ormiston JA; Serruys PW
    Eur Heart J; 2012 Jun; 33(11):1325-33. PubMed ID: 22507972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative assessment of "plaque/media" change on three modalities of IVUS immediately after implantation of either everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent in Absorb II study.
    Zeng Y; Cavalcante R; Tenekecioglu E; Suwannasom P; Sotomi Y; Collet C; Abdelghani M; Jonker H; Digne F; Horstkotte D; Zehender M; Indolfi C; Saia F; Fiorilli R; Chevalier B; Bolognese L; Goicolea J; Nie S; Onuma Y; Serruys PW;
    Int J Cardiovasc Imaging; 2017 Apr; 33(4):441-449. PubMed ID: 28012050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronary Artery Vessel Healing Pattern, Short and Long Term, After Implantation of the Everolimus-Eluting Bioresorbable Vascular Scaffold.
    Kraak RP; de Boer HH; Elias J; Ambarus CA; van der Wal AC; de Winter RJ; Wykrzykowska JJ
    J Am Heart Assoc; 2015 Nov; 4(11):. PubMed ID: 26553215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
    Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
    Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial.
    Gogas BD; Serruys PW; Diletti R; Farooq V; Brugaletta S; Radu MD; Heo JH; Onuma Y; van Geuns RJ; Regar E; De Bruyne B; Chevalier B; Thuesen L; Smits PC; Dudek D; Koolen J; Windecker S; Whitbourn R; Miquel-Hebert K; Dorange C; Rapoza R; Garcia-Garcia HM; McClean D; Ormiston JA
    JACC Cardiovasc Interv; 2012 Jun; 5(6):656-65. PubMed ID: 22721662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphological, Functional, and Biological Vascular Healing Response 6 Months After Drug-Eluting Stent Implantation: A Randomized Comparison of Three Drug-Eluting Stents.
    Nakata T; Fujii K; Fukunaga M; Shibuya M; Kawai K; Kawasaki D; Naito Y; Ohyanagi M; Masuyama T
    Catheter Cardiovasc Interv; 2016 Sep; 88(3):350-7. PubMed ID: 26526816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent.
    Ishibashi Y; Muramatsu T; Nakatani S; Sotomi Y; Suwannasom P; Grundeken MJ; Cho YK; Garcia-Garcia HM; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; McClean D; de Sousa Almeida M; Wasungu L; Miquel-Hebert K; Dudek D; Chevalier B; Onuma Y; Serruys PW
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1053-1063. PubMed ID: 26205444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.